Friday, 16 October 2026European Markets

DEKUPLE And PUBLICIS GROUPE SA Have A High Dividend Yield And Return On Equity In The Advertising Agencies Industry.

Loading stream...

(vianews) - dekuple (dkupl.pa) is among this list of stock assets with the highest dividend rate and return on equity on the advertising agencies industry.

financial asset price forward dividend yield return on equity
dekuple (dkupl.pa) €26.30 3.17% 37.16%
publicis groupe sa (pub.pa) €70.52 3.16% 13.46%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. dekuple (dkupl.pa)

3.17% forward dividend yield and 37.16% return on equity

adlpartner sa provides marketing solutions in france and internationally. the company markets and sells press subscriptions; and offers cross-channel marketing solutions and insurance brokerage services. it also provides consulting and technology, marketing engineering, and creator of customer relation services. the company was founded in 1972 and is based in montreuil, france. adlpartner sa is a subsidiary of sogespa sas.

earnings per share

as for profitability, dekuple has a trailing twelve months eps of €1.8.

pe ratio

dekuple has a trailing twelve months price to earnings ratio of 14.62. meaning, the purchaser of the share is investing €14.62 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 37.16%.

more news about dekuple.

2. publicis groupe sa (pub.pa)

3.16% forward dividend yield and 13.46% return on equity

publicis groupe s.a. provides marketing, communications, and digital business transformation services in north america, europe, the asia pacific, latin america, africa, and the middle east. the company offers advisory services for brand strategy, and repositioning and their identity under the publicis worldwide, saatchi & saatchi, leo burnett, marcel, fallon, and bbh brands; online advertising services under the razorfish and moxie brand names; crisis communications, press relations, public affairs, financial communications, and strategy management services; media consulting, planning, and buying services; performance marketing services; and e-commerce services. it also designs and delivers brand content for various channels, such as television, print, radio, cinema, and billboards, as well as digital, including display, and social networks under the prodigious, harbor, and the pub brand names. in addition, the company operates epsilon peoplecloud, a unified data and technology platform; and publicis sapient, a technological, digital, and consulting platform. further, it provides healthcare communication services under the digitas health, publicis health media, and saatchi & saatchi wellness brands for the healthcare and well-being sectors. the company serves clients in the automotive, retail, financial services, consumer products, and media sectors. publicis groupe s.a. was founded in 1926 and is headquartered in paris, france.

earnings per share

as for profitability, publicis groupe sa has a trailing twelve months eps of €4.4.

pe ratio

publicis groupe sa has a trailing twelve months price to earnings ratio of 16.03. meaning, the purchaser of the share is investing €16.03 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.46%.

more news about publicis groupe sa.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com